Top Regulatory Mistakes Companies Make (and How to Avoid Them)

Most regulatory failures don’t stem from a single bad decision. They develop quietly, over time, through small oversights that compound into significant compliance risk.

In regulated industries — including natural health products, food and beverage, cosmetics, pharmaceuticals, and cannabis — enforcement actions, audits, recalls, and legal exposure often trace back to the same underlying issues. These issues are not always technical in nature. More often, they reflect gaps in governance, quality systems, and regulatory strategy.

Understanding where companies commonly go wrong is one of the most effective ways to reduce regulatory risk.

Mistake 1: Treating Product Compliance as a One-Time Exercise

One of the most common mistakes is viewing regulatory compliance as a milestone achievement rather than an ongoing obligation that adapts with the times.

Companies often invest heavily to secure product approval or market entry, only to shift focus once the product is launched. However, regulators evaluate compliance across the entire product lifecycle. Manufacturing changes, new suppliers, formulation updates, and evolving claims all affect regulatory standing.

When compliance systems are not maintained or reviewed regularly, gaps appear. Unfortunately, these tend to go unnoticed until an inspection or customer complaint brings them to light.

Mistake 2: Over-Reliance on Checklists and Templates

Checklists can be useful tools, but they are not a substitute for regulatory judgment.

Relying too heavily on templates, generic SOPs, or copied documentation often results in systems that look compliant on paper but fail under scrutiny. Regulators increasingly assess whether procedures are appropriate for the specific product, process, and risk profile, and whether they are followed as intended. A quality system that isn’t tailored to how a company actually operates is difficult to defend when questioned.

Mistake 3: Weak Documentation and Poor Data Integrity

Documentation failures remain one of the most frequent drivers of inspection findings.

Common issues include incomplete records, inconsistent data, undocumented decisions, or an inability to trace how risks were assessed and managed. In many cases, the work may have been done correctly, but without clear records, there is no evidence to support it.

As regulatory oversight becomes more data-driven, poor documentation is increasingly viewed as a systemic quality failure rather than an administrative oversight.

Mistake 4: Underestimating Supplier and Contract Manufacturer Risk

Outsourcing does not transfer regulatory responsibility from one company to another.

Companies that rely on third-party manufacturers, laboratories, or suppliers often assume those partners are fully compliant. In reality, regulators expect the product owner or licence holder to demonstrate active oversight of the process to ensure compliance. 

Missing quality agreements, outdated supplier audits, or unclear accountability can quickly escalate into serious compliance issues — especially when products are imported or manufactured outside Canada.

Mistake 5: Disconnect Between Regulatory, Quality, and R&D Teams

Regulatory risk often increases when departments operate in silos.

Formulation changes made without regulatory review, quality decisions made without scientific context, or regulatory strategies developed without operational input can all lead to misalignment. Over time, these disconnects weaken the defensibility of the overall compliance program.

Strong organizations treat regulatory, quality, and R&D functions as integrated components of a single system.

Mistake 6: Waiting for an Inspection to Fix Problems

Reactive compliance is expensive and can also hurt a company’s reputation.

Many organizations only address known gaps after an inspection, complaint, or enforcement action. By that point, timelines are compressed, regulators are engaged, and options are limited.

Proactive gap assessments, internal audits, and system reviews enable companies to identify and remediate weaknesses before they lead to regulatory findings.

Mistake 7: Lack of Senior Management Accountability

Regulators increasingly expect visible leadership involvement in compliance and quality decisions.

When senior management is disengaged from regulatory oversight, quality systems often lack authority, resources, or follow-through. This becomes apparent during inspections, particularly when corrective actions stall or recurring issues persist.

A strong compliance culture starts at the top.

How to Reduce Regulatory Risk

Avoiding these mistakes does not require perfection — but it does require intention and awareness. Effective regulatory risk management depends on:

• Quality systems that reflect real operations
• Clear, defensible documentation
• Active supplier oversight
• Integrated decision-making across teams
• Ongoing review and improvement
  

Companies that invest in these fundamentals are better positioned to respond to inspections, defend their products, and adapt to evolving regulatory expectations.

How MCS Associates Can Help Regulated Industries 

At MCS Associates, we work with organizations across regulated industries to identify regulatory risk before it becomes a problem.

Our regulatory services include: 

• Regulatory gap assessments
• GMP and QMS audits
• Supplier oversight programs
• Documentation reviews and strategic advisory support. 

We help clients move beyond reactive compliance toward systems that are practical, proportionate, and defensible.

Learning from Mistakes Before They Become Findings

Regulatory success is rarely about doing more. It’s about doing the right things, consistently and with evidence. By understanding where companies most often stumble — and why — organizations can strengthen their systems, protect market access, and reduce long-term risk.

Contact MCS Associates to learn more about regulatory mistakes and how we can help you plan effectively to reduce your risks.

Resources:

• Health Canada. Compliance and Enforcement Policy for Health Products.
  https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement.html
• Health Canada. Good Manufacturing Practices Guidance Documents. https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/guidance-documents.html
• U.S. Food and Drug Administration. Inspections, Compliance, Enforcement, and Criminal Investigations.
  https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations